06:47:48 Europe / Stockholm
Svenska | English

2cureX

Attachments

Share price & Turnover

Share price change and turnover during the day of this press release

Subscription

Calendar

2025-02-27 Year-end Report 2024
2024-08-22 Quarterly Report 2024-Q2
2024-05-24 Ex-date Ordinary Dividend 2CUREX 0.00 SEK
2024-05-23 Annual General meeting
2024-02-29 Extra General Meeting 2024
2024-02-22 Year-end Report 2023
2023-11-23 Quarterly Report 2023-Q3
2023-11-14 Extra General Meeting 2023
2023-08-24 Quarterly Report 2023-Q2
2023-05-29 Quarterly Report 2023-Q1
2023-05-26 Ex-date Ordinary Dividend 2CUREX 0.00 SEK
2023-05-25 Annual General meeting
2023-02-23 Year-end Report 2022
2023-02-10 Extra General Meeting 2022
2022-11-24 Quarterly Report 2022-Q3
2022-08-25 Quarterly Report 2022-Q2
2022-05-25 Ex-date Ordinary Dividend 2CUREX 0.00 SEK
2022-05-24 Quarterly Report 2022-Q1
2022-05-24 Annual General meeting
2022-02-24 Year-end Report 2021
2021-11-25 Quarterly Report 2021-Q3
2021-08-26 Quarterly Report 2021-Q2
2021-05-28 Ex-date Ordinary Dividend 2CUREX 0.00 SEK
2021-05-27 Annual General meeting
2021-05-27 Quarterly Report 2021-Q1
2021-02-25 Year-end Report 2020
2020-11-26 Quarterly Report 2020-Q3
2020-08-27 Quarterly Report 2020-Q2
2020-07-02 Extra General Meeting 2020
2020-05-29 Ex-date Ordinary Dividend 2CUREX 0.00 SEK
2020-05-28 Quarterly Report 2020-Q1
2020-05-28 Annual General meeting
2020-02-28 Year-end Report 2019
2019-11-22 Quarterly Report 2019-Q3
2019-08-23 Quarterly Report 2019-Q2
2019-05-29 Ex-date Ordinary Dividend 2CUREX 0.00 SEK
2019-05-28 Annual General meeting
2019-05-17 Quarterly Report 2019-Q1
2019-04-02 Extra General Meeting 2019
2019-03-01 Year-end Report 2018
2018-11-23 Quarterly Report 2018-Q3
2018-08-24 Quarterly Report 2018-Q2
2018-05-29 Ex-date Ordinary Dividend 2CUREX 0.00 SEK
2018-05-28 Annual General meeting
2018-05-18 Quarterly Report 2018-Q1
2018-02-15 Year-end Report 2017

Description

CountryDenmark
ListFirst North Stockholm
SectorHealth care
IndustryMedical technology
2cureX är verksamt inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Störst verksamhet innehas på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2cureX will be holding its Q3 2023 online presentation with a Q&A session on October 26, 2023 at 20.00 (CET).
2023-10-03 09:15:00

2cureX Management will present status on the published goals for 2023 and additional important achievements.

The Q&A session will be hosted by Stokk.io and will allow you to submit questions from today and during the live event. You can sign up via the following link: Q&A webcast for Q3 2023. Stokk.io will act as moderator during the session.

The Q&A event will be livestreamed on the same link. The event is recorded and transcribed and made available for all investors afterwards on our website. 

The full quarterly report will be published on November 23 and a video commentary will be held on the same day (hosted by Infront Direkt).

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
 
Certified Adviser: Redeye AB

Attachments

2cureX will be holding its Q3 2023 online presentation with a Q&A session on October 26, 2023 at 20.00 (CET).

Source MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

An email has been sent to the given address. To login please click "Login" in that email to verify your account

Companies

Press releases